Cargando…

Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus

BACKGROUND: To analyze the change and clinical significance of cortisol, B-type brain natriuretic peptide (BNP), and prostacyclin-2 (PGE-2) levels in premature infants with patent ductus arteriosus (PDA). METHODS: A total of 67 cases of premature infants admitted to our hospital from January 2018 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Qintao, Liu, Xiaochen, Su, Guobao, Zhou, Chaoyuan, Wang, Junhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578766/
https://www.ncbi.nlm.nih.gov/pubmed/34765481
http://dx.doi.org/10.21037/tp-21-450
_version_ 1784596304256565248
author Cui, Qintao
Liu, Xiaochen
Su, Guobao
Zhou, Chaoyuan
Wang, Junhua
author_facet Cui, Qintao
Liu, Xiaochen
Su, Guobao
Zhou, Chaoyuan
Wang, Junhua
author_sort Cui, Qintao
collection PubMed
description BACKGROUND: To analyze the change and clinical significance of cortisol, B-type brain natriuretic peptide (BNP), and prostacyclin-2 (PGE-2) levels in premature infants with patent ductus arteriosus (PDA). METHODS: A total of 67 cases of premature infants admitted to our hospital from January 2018 to April 2020 were included, all of whom developed PDA (PDA group). According to the presence or absence of symptoms, they were divided into the symptomatic group (28 cases) and the asymptomatic group (39 cases). In addition, 62 premature infants without PDA who were born in our hospital during the same period were selected as the control group. The expression levels of cortisol, BNP, and PGE-2 in infants in different groups and between infants with symptoms and without symptoms were analyzed, along with the risk factors leading to PDA in preterm infants. The value of cortisol, BNP, and PGE-2 in the diagnosis of PDA in premature infants was also analyzed. RESULTS: Compared with the control group, cortisol in the PDA group was significantly decreased (P<0.05), while the levels of BNP and PGE-2 were significantly increased (P<0.05). The cortisol level in the asymptomatic group was significantly higher than that in the symptomatic group, while the levels of BNP and PGE-2 were opposite, and the differences were statistically significant (P<0.05). Logistic regression analysis showed that birth weight <1,200 g, decreased cortisol, increased BNP, and increased PGE-2 were independent risk factors leading to PDA in preterm infants, and the differences were statistically significant (P<0.05). Receiver operating characteristic (ROC) curve showed that the sensitivity and specificity of cortisol+BNP+PGE-2 in the diagnosis of PDA in premature infants were 75.60% and 73.10%, respectively. The area under the curve (AUC) value was 0.759 (95% CI: 0.611–0.859), which was significantly higher than the AUC values of the 3 tests alone (P<0.05). CONCLUSIONS: The expression of cortisol decreased in premature infants with PDA, while the levels of BNP and PGE-2 significantly increased. Dynamic detection of the changes in these levels can provide an important reference for the early diagnosis of PDA and for the assessment of disease progression.
format Online
Article
Text
id pubmed-8578766
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85787662021-11-10 Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus Cui, Qintao Liu, Xiaochen Su, Guobao Zhou, Chaoyuan Wang, Junhua Transl Pediatr Original Article BACKGROUND: To analyze the change and clinical significance of cortisol, B-type brain natriuretic peptide (BNP), and prostacyclin-2 (PGE-2) levels in premature infants with patent ductus arteriosus (PDA). METHODS: A total of 67 cases of premature infants admitted to our hospital from January 2018 to April 2020 were included, all of whom developed PDA (PDA group). According to the presence or absence of symptoms, they were divided into the symptomatic group (28 cases) and the asymptomatic group (39 cases). In addition, 62 premature infants without PDA who were born in our hospital during the same period were selected as the control group. The expression levels of cortisol, BNP, and PGE-2 in infants in different groups and between infants with symptoms and without symptoms were analyzed, along with the risk factors leading to PDA in preterm infants. The value of cortisol, BNP, and PGE-2 in the diagnosis of PDA in premature infants was also analyzed. RESULTS: Compared with the control group, cortisol in the PDA group was significantly decreased (P<0.05), while the levels of BNP and PGE-2 were significantly increased (P<0.05). The cortisol level in the asymptomatic group was significantly higher than that in the symptomatic group, while the levels of BNP and PGE-2 were opposite, and the differences were statistically significant (P<0.05). Logistic regression analysis showed that birth weight <1,200 g, decreased cortisol, increased BNP, and increased PGE-2 were independent risk factors leading to PDA in preterm infants, and the differences were statistically significant (P<0.05). Receiver operating characteristic (ROC) curve showed that the sensitivity and specificity of cortisol+BNP+PGE-2 in the diagnosis of PDA in premature infants were 75.60% and 73.10%, respectively. The area under the curve (AUC) value was 0.759 (95% CI: 0.611–0.859), which was significantly higher than the AUC values of the 3 tests alone (P<0.05). CONCLUSIONS: The expression of cortisol decreased in premature infants with PDA, while the levels of BNP and PGE-2 significantly increased. Dynamic detection of the changes in these levels can provide an important reference for the early diagnosis of PDA and for the assessment of disease progression. AME Publishing Company 2021-10 /pmc/articles/PMC8578766/ /pubmed/34765481 http://dx.doi.org/10.21037/tp-21-450 Text en 2021 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Cui, Qintao
Liu, Xiaochen
Su, Guobao
Zhou, Chaoyuan
Wang, Junhua
Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus
title Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus
title_full Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus
title_fullStr Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus
title_full_unstemmed Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus
title_short Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus
title_sort change and clinical significance of serum cortisol, bnp, and pge-2 levels in premature infants with patent ductus arteriosus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578766/
https://www.ncbi.nlm.nih.gov/pubmed/34765481
http://dx.doi.org/10.21037/tp-21-450
work_keys_str_mv AT cuiqintao changeandclinicalsignificanceofserumcortisolbnpandpge2levelsinprematureinfantswithpatentductusarteriosus
AT liuxiaochen changeandclinicalsignificanceofserumcortisolbnpandpge2levelsinprematureinfantswithpatentductusarteriosus
AT suguobao changeandclinicalsignificanceofserumcortisolbnpandpge2levelsinprematureinfantswithpatentductusarteriosus
AT zhouchaoyuan changeandclinicalsignificanceofserumcortisolbnpandpge2levelsinprematureinfantswithpatentductusarteriosus
AT wangjunhua changeandclinicalsignificanceofserumcortisolbnpandpge2levelsinprematureinfantswithpatentductusarteriosus